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Evidence of spinal cord involvement in Powassan virus in-
fection is largely limited to mouse models. We report a case 
of a polio-like illness caused by Powassan virus infection in 
a 62-year-old man in Canada. Magnetic resonance imag-
ing showed T2 hyperintensities in the anterior horns of the 
cervical spinal cord.
Powassan virus (POWV) is a tickborne flavivirus, named after Powassan, Ontario, Canada, the location of the 
first documented human infection in 1958 (1). Since then, 
≈150 cases of POWV infection have been reported glob-
ally, and incidence has increased over time. A total of 125 
POWV cases have been identified since 2008, 33 (26%) in 
2017 (2). In Canada, most reported POWV infections have 
been in the Great Lakes region. A small number of cases 
have been reported in the Maritime provinces (3). 
POWV is transmitted by members of the Ixodes genus 
of ticks, including I. cookei and the more opportunistic and 
aggressive I. scapularis. POWV has 2 lineages; lineage 2 
(deer tick virus) has emerged quickly in parts of North Amer-
ica, along with the expanding range of I. scapularis ticks.
POWV infection typically begins with prodromal 
symptoms including fever, nausea, headache, and myalgia. 
Central nervous system involvement includes an altered 
level of consciousness, paralysis, or ophthalmoplegia (4). 
POWV encephalitis has a 10% mortality rate, and <50% 
of survivors suffer residual deficits (5). Studies with mice 
have demonstrated that POWV can affect motor neurons 
in the anterior horns of the spinal cord (6). These same 
neurons are affected by poliovirus, West Nile virus, and 
enterovirus D68 (7). However, POWV infection with cord 
involvement in humans is not well documented; 1 human 
case demonstrated motor neuron pathology after POWV 
lineage 2 infection (8), and a second case with suspected 
motor neuronopathy was reported in 2018 (9).
We present the case of a 62-year-old man living in 
urban Ontario who experienced nausea, vomiting, and 
abdominal pain while vacationing in rural Newfoundland. 
He sought treatment at a hospital in Nova Scotia and expe-
rienced diplopia and ataxia. A computed tomography scan 
of the head did not show any acute intracranial event.
The patient became febrile and experienced dysar-
thria, weakness, and respiratory distress. Cerebrospinal 
fluid analysis showed pleocytosis (159 × 106 total nucle-
ated cells: 42% neutrophils, 43% lymphocytes) and el-
evated protein levels (0.79 g/L). He was started on em-
piric treatment with ceftriaxone, ampicillin, acyclovir, 
and dexamethasone. Results of tests for Cryptococcus, 
HIV, syphilis, Lyme disease, herpes simplex viruses 1 and 
2, varicella zoster virus, and acid-fast bacilli were nega-
tive. Initial arbovirus serology results were negative. The 
patient worsened, requiring intubation and transfer to an 
intensive care unit.1These first authors contributed equally to this article.
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Seven days after arriving at the hospital, the patient 
was unable to lift his arms and was transferred to a tertiary 
center in Ottawa, Ontario (The Ottawa Hospital). Neuro-
logic exam showed facial and extraocular muscle weak-
ness. He had flaccid tone and absent power in his upper 
extremities and reduced strength in his lower extremities. 
Sensation was preserved. Nerve conduction studies dem-
onstrated diffusely low motor amplitudes, normal sensory 
amplitudes, and normal conduction velocities suggestive 
of a motor neuronopathy. Electromyography in the acute 
phase was not possible due to poor patient cooperation.
Results of paired convalescent arbovirus serology col-
lected 1 month after symptom onset were positive. Test-
ing at the National Microbiology Laboratory confirmed 
POWV infection (hemagglutination inhibition titer 1:80, 
plaque-reduction neutralization titer 1:160). Magnetic res-
onance imaging (MRI) of the brain showed infratentorial 
and supratentorial leptomeningeal enhancement. An MRI 
of the cervical spine showed increased T2-weighted signal 
involving the anterior horns from C3 to C6 (Figure; Appen-
dix Figure, https://wwwnc.cdc.gov/EID/article/25/8/19-
0399-App1.pdf).
Follow-up MRI of the brain and spine 1 month later 
showed interval resolution of leptomeningeal abnormali-
ties, but abnormal signal within the anterior horn of the 
cervical spine remained. Electrodiagnostic testing repeated 
6 months after symptom onset again showed normal senso-
ry nerve conduction studies and abnormal motor nerve con-
duction studies. There was diffuse denervation in all cervi-
cal myotomes including the paraspinal muscles, confirming 
a motor neuronopathy consistent with a poliomyelitis-like 
presentation of POWV. We suspect that initial arbovirus 
serology was performed too early in the disease course, be-
cause paired serology 4 weeks later demonstrated serocon-
version and confirmed diagnosis.
Our case shares similarities with a recently published 
report of POWV infection (9). In that case, a patient va-
cationing in the Luskville region of Quebec, Canada, ex-
perienced cranial nerve pathologies and flaccid weakness 
of the upper extremities. Electrodiagnostic testing showed 
evidence of diffuse denervation and reinervation across 
multiple myotomes that was consistent with a motor neu-
ronopathy. Imaging of the brain showed only mild hyper-
intensities that would not account for the patient’s dispro-
portionate weakness. A spinal MRI was not performed. As 
in our case, acute arbovirus serology results were initially 
negative but were positive in paired testing (9).
The incidence of POWV infection has increased since 
2017 (7).  I. scapularis ticks and deer tick virus may be be-
coming more widely disseminated in northern regions, po-
tentially due to warming climates, whereas infection with 
prototypical POWV transmitted by I. cookei ticks remains 
rare and stable in distribution (10). It is possible that Can-
ada will see an increasing number of cases similar to ours. 
Our findings emphasize the need to include POWV infec-
tion in the differential diagnosis for patients with polio-like 
symptoms in tick-endemic regions.
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From the Greek polios (“gray”) + myelos (“marrow”), polio-myelitis may have plagued humanity since antiquity. The 
funerary stele of the Egyptian priest Ruma (circa 1400 BCE) 
shows a shortened, withered leg, in what is believed to be one 
of the earliest depictions of polio. The first clinical description 
was in 1789 by Michael Underwood. Karl Landsteiner and Er-
win Popper identified poliovirus in 1908, and 40 years later 
John Enders, Thomas Weller, and Frederick Robbins were able 
to grow poliovirus in tissue culture cells, work for which they 
received the Nobel Prize in Medicine or Physiology in 1954. 
This breakthrough facilitated vaccine research, and the first in-
activated polio vaccine, developed by Jonas Salk and his team, 
was licensed in 1955. Six years later, Albert Sabin and his team 
developed a live, attenuated oral polio vaccine.
Because broad immunization campaigns made progress 
toward regional polio elimination in the Americas, in 1988 the 
World Health Assembly declared a goal of global polio eradi-
cation. Through a partnership between Rotary International, the 
World Health Organization, the United Nations Children’s Fund, 
the Centers for Disease Control and Prevention, and the Bill & 
Melinda Gates Foundation, the Global Polio Eradication Initia-
tive has achieved a 99.9% decrease in the global incidence of 
polio. Today, wild poliovirus transmission occurs in only Af-
ghanistan and Pakistan, and 4 of the 6 World Health Organization 
regions have formally declared the elimination of the indigenous 
wild poliovirus. Of the 3 types of poliovirus, type 2 wild polio-
virus was declared eradicated globally in 2015, and type 3 wild 
poliovirus has not been detected since 2012. With only 33 cases 
globally from type 1 wild poliovirus in 2018, the task remains to 
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This historic 1975 photograph shows a laboratory technician preparing doses of polio 
vaccine by placing a liquid droplet of the vaccine on each of these sugar cubes, which 
would subsequently be ingested orally by each recipient. Photo: Public Health Image 
Library, Centers for Disease Control and Prevention, 1975.
